AI in optimized cancer treatment: laying the groundwork for interdisciplinary progress
The molecular complexity of cancer presents significant challenges to traditional therapeutic approaches, necessitating the development of innovative treatment strategies capable of addressing the disease's dynamic nature and resistance mechanisms. Data-driven methodologies, particularly those employing Artificial Intelligence (AI), hold substantial promise by advancing a comprehensive understanding of the intricate molecular and cellular mechanisms underlying cancer and supporting the development of adaptive, patient-specific therapeutic strategies. Initiated through the Mertelsmann Foundation, the Collaborative Research Institute Intelligent Oncology (CRIION) in Freiburg im Breisgau, Germany, aims to drive progress in AI-driven oncology. CRIION fosters global collaboration through initiatives like the Intelligent Oncology Symposium and supports multidisciplinary projects designed to integrate AI innovations into clinical workflows.
Authors
- Evelyn Ullrich (ORCID: https://orcid.org/0000-0001-8530-1192)
- Gabriel Kalweit (ORCID: https://orcid.org/0000-0003-4581-8810)
- Joschka Boedecker (ORCID: https://orcid.org/0000-0002-3486-7345)
- Roland Mertelsmann
Institutions
- Goethe University Frankfurt (DE)
- University of Freiburg (DE)
- German Cancer Research Center (DE)
- University Medical Center Freiburg (DE)
- Bernstein Center for Computational Neuroscience Freiburg (DE)
- German Cancer Society (DE)
- Collaborative Research Group (AU)
- University of Education Freiburg (DE)
- Protestant University of Applied Sciences Freiburg (DE)
- Frankfurt Cancer Institute (DE)
Publication Details
- Journal
- Oxford Open Immunology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/oxfimm/iqaf004
- Citations
- 3
- Primary Topic
- Artificial Intelligence in Healthcare and Education
- Type
- article
- Field-Weighted Citation Impact
- 1.96